Neuregulin-1 beta 1 is implicated in pathogenesis of multiple sclerosis

Multiple sclerosis is characterized by immune mediated neurodegeneration that results in progressive, life-long neurological and cognitive impairments. Yet, the endogenous mechanisms underlying multiple sclerosis pathophysiology are not fully understood. Here, we provide compelling evidence that associates dysregulation of neuregulin-1 beta 1 (Nrg-1 beta 1) with multiple sclerosis pathogenesis and progression. In the experimental autoimmune encephalomyelitis model of multiple sclerosis, we demonstrate that Nrg-1 beta 1 levels are abated within spinal cord lesions and peripherally in the plasma and spleen during presymptomatic, onset and progressive course of the disease. We demonstrate that plasma levels of Nrg-1 beta 1 are also significantly reduced in individuals with early multiple sclerosis and is positively associated with progression to relapsing-remitting multiple sclerosis. The functional impact of Nrg-1 beta 1 downregulation preceded disease onset and progression, and its systemic restoration was sufficient to delay experimental autoimmune encephalomyelitis symptoms and alleviate disease burden. Intriguingly, Nrg-1 beta 1 therapy exhibited a desirable and extended therapeutic time window of efficacy when administered prophylactically, symptomatically, acutely or chronically. Using in vivo and in vitro assessments, we identified that Nrg-1 beta 1 treatment mediates its beneficial effects in EAE by providing a more balanced immune response. Mechanistically, Nrg-1 beta 1 moderated monocyte infiltration at the blood-CNS interface by attenuating chondroitin sulphate proteoglycans and MMP9. Moreover, Nrg-1 beta 1 fostered a regulatory and reparative phenotype in macrophages, T helper type 1 (Th1) cells and microglia in the spinal cord lesions of EAE mice. Taken together, our new findings in multiple sclerosis and experimental autoimmune encephalomyelitis have uncovered a novel regulatory role for Nrg-1 beta 1 early in the disease course and suggest its potential as a specific therapeutic target to ameliorate disease progression and severity.

Automated summary

Multiple sclerosis is characterized by immune mediated neurodegeneration, and dysregulation of neuregulin-1 beta 1 (Nrg-1 beta 1) has been associated with the pathogenesis and progression of the disease. Nrg-1 beta 1 levels are reduced in early multiple sclerosis patients, and systemic restoration of Nrg-1 beta 1 can delay symptoms and alleviate disease burden in experimental models. Nrg-1 beta 1 therapy shows promising effects in regulating immune response and may serve as a therapeutic target for ameliorating disease progression and severity.